🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

136+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 136 recruiting trials for “plasmablastic-lymphoma

Phase 2RecruitingNCT06477549

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

🏥 St. Petersburg State Pavlov Medical University📍 1 site📅 Started Jun 2024View details ↗
EARLY_Phase 1RecruitingNCT06514768

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

👨‍⚕️ Sanbin Wang, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China📍 1 site📅 Started Jun 2024View details ↗
NARecruitingNCT06481228

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

👨‍⚕️ Jianxiang Wang, Dr, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jun 2024View details ↗
EARLY_Phase 1RecruitingNCT06346912

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

👨‍⚕️ He Huang, MD, Zhejiang University📍 1 site📅 Started May 2024View details ↗
Phase 1RecruitingNCT06195891

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

👨‍⚕️ Amandeep Salhotra, City of Hope Medical Center📍 1 site📅 Started May 2024View details ↗
Phase 1, PHASE2RecruitingNCT06635330

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

🏥 Kara Yakhteh Tajhiz Azma Company📍 1 site📅 Started May 2024View details ↗
Phase 2RecruitingNCT06508099

Vitamin A and D Supplementation in Allogeneic HCT

🏥 St. Petersburg State Pavlov Medical University📍 1 site📅 Started May 2024View details ↗
Phase 2RecruitingNCT05800210

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

👨‍⚕️ Jordan Milner, MD, University of Florida📍 1 site📅 Started May 2024View details ↗
Phase 2RecruitingNCT06393985

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

👨‍⚕️ Xiaowen Tang, Ph.D, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Apr 2024View details ↗
NARecruitingNCT06343090

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

🏥 Beijing GoBroad Hospital📍 1 site📅 Started Apr 2024View details ↗
RecruitingNCT06025682

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

👨‍⚕️ Livio Pagano, Policlinico Universitario A. Gemelli, IRCCS-Università Cattolica del Sacro Cuore, Roma📍 1 site📅 Started Apr 2024View details ↗
Phase 1RecruitingNCT06287528

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

👨‍⚕️ Jae Park, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Feb 2024View details ↗
Phase 1RecruitingNCT04881240

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

👨‍⚕️ Aimee C. Talleur, MD, St. Jude Children's Research Hospital📍 1 site📅 Started Feb 2024View details ↗
Phase 1RecruitingNCT06508463

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

👨‍⚕️ Kah Whye Peng, PhD, Mayo Clinic in Rochester📍 2 sites📅 Started Jan 2024View details ↗
Phase 2RecruitingNCT06144606

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

👨‍⚕️ Bijal D. Shah, MD, Moffitt Cancer Center📍 1 site📅 Started Dec 2023View details ↗
NARecruitingNCT06783816

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

🏥 Shanxi Bethune Hospital📍 1 site📅 Started Dec 2023View details ↗
Phase 1RecruitingNCT06173518

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

🏥 Autolus Limited📍 8 sites📅 Started Nov 2023View details ↗
Phase 1, PHASE2RecruitingNCT05658640

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

👨‍⚕️ Paco Bautista, MD PhD, Princess Máxima Center📍 36 sites📅 Started Nov 2023View details ↗
Phase 1, PHASE2RecruitingNCT06082934

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

🏥 Xijing Hospital📍 1 site📅 Started Nov 2023View details ↗
Phase 1RecruitingNCT05995028

Universal 4SCAR7U Targeting CD7-positive Malignancies

🏥 Shenzhen Geno-Immune Medical Institute📍 1 site📅 Started Oct 2023View details ↗
← PreviousPage 4 of 7Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →